What question did this study set out to answer?

The research aims to assess the efficacy of cefepime-enmetazobactam against ESBL- and AmpC-producing Enterobacterales.

Combating antimicrobial resistance in ESBL- and AmpC-producing Enterobacterales: In vitro evaluation of cefepime–enmetazobactam

View Full Paper

Ask AI

Bookmark

Authors

Laboratory evaluation shows cefepime–enmetazobactam is effective against resistant Enterobacterales, suggesting a new treatment option.

The research aims to assess the efficacy of cefepime-enmetazobactam against ESBL- and AmpC-producing Enterobacterales.
Conducted a prospective laboratory study with 147 clinically isolated Enterobacterales.
Determined susceptibility using the Kirby–Bauer disk diffusion method according to EUCAST guidelines.
Compared FEP-EMT activity with other beta-lactam combinations.
95.2% of ESBL- and/or AmpC isolates were susceptible to FEP-EMT.
FEP-EMT showed superior efficacy compared to cefaperazone-sulbactam (88.7%), piperacillin-tazobactam (73.4%), and amoxicillin-clavulanic acid (63.0%).
FEP-EMT restored susceptibility to cefepime in 97.8% of isolates.

Haleangadi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark